Ouvrages publiés en collaboration (2)
  1. 1. Soubhye, J., Furtmüller, P. G., Dufrasne, F., & Obinger, C. (2021). Reactive oxygen species.
  2. 2. Neve, J., Dufrasne, F., & Van Antwerpen, P. (2008). Etude des Médicaments: Médicaments Organiques. Bruxelles: Presses Universitaires de Bruxelles.
    3.   Parties d'ouvrages collectifs (1)
  3. 1. Soubhye, J., Furtmueller, P. G., Dufrasne, F., & Obinger, C. (2021). Reactive oxygen species: Inhibition of Myeloperoxidase. In H. H. Schmidt & Ghezzi (Eds.), Inhibition of Myeloperoxidase, Vol. 264. Reactive oxygen species (1 ed., pp. 261-285). Cham, Switzerland: Springer.(Handbook of experimental pharmacology). doi:10.1007/978-3-030-68510-2
    4.   Articles dans des revues avec comité de lecture (55)
  4. 1. Dufrasne, F. (2024). Immune Diseases: Challenges, Hopes and Recent Achievements. Pharmaceuticals, 17(1), 97. doi:10.3390/ph17010097
  5. 2. Yang, D., Zhang, Y., Sow, I. S., Liang, H., El Manssouri, N., Gelbcke, M., Dong, L., Chen, G., Dufrasne, F., Fontaine, V., & Li, R. (2023). Antimycobacterial Activities of Hydroxamic Acids and Their Iron(II/III), Nickel(II), Copper(II) and Zinc(II) Complexes. Microorganisms, 11(10), 2611. doi:10.3390/microorganisms11102611
  6. 3. Cuypers, L., Keyaerts, E., Hong, S. L., Gorissen, S., Menezes, S. M., Starick, M., Van Elslande, J., Weemaes, M., Wawina-Bokalanga, T., Marti-Carreras, J., Vanmechelen, B., Van Holm, B., Bloemen, M., Dogne, J.-M., Dufrasne, F., Durkin, K., Ruelle, J., De Mendonça, R., Wollants, E., Vermeersch, P., COVID-19 Genomics Belgium Consortium,, Boulouffe, C., Djiena, A., Broucke, C., Catry, B., Lagrou, K., Van Ranst, M., Neyts, J., Baele, G., Maes, P., André, E., Dellicour, S., Van Weyenbergh, J., et al. (2023). Immunovirological and environmental screening reveals actionable risk factors for fatal COVID-19 during post-vaccination nursing home outbreaks. Nature aging, 3(6), 722-733. doi:10.1038/s43587-023-00421-1
  7. 4. Sow, I. S., Gelbcke, M., Dufrasne, F., & Robeyns, K. (2023). Crystal Structures of a Series of Hydroxamic Acids. Molbank, 2023, 1637.
  8. 5. Sow, I. S., Gelbcke, M., Meyer, F., Vandeput, M., Marloye, M., Basov, S., Van Bael, M., Berger, G., Robeyns, K., Hermans, S., Yang, D., Fontaine, V., & Dufrasne, F. (2023). Synthesis and biological activity of iron(II), iron(III), nickel(II), copper(II) and zinc(II) complexes of aliphatic hydroxamic acids. Journal of coordination chemistry, 1-30. doi:10.1080/00958972.2023.2166407
  9. 6. Marloye, M., Inam, H., Moore, C. J., Mertens, T. R., Ingels, A., Koch, M., Nowicki, M. O., Mathieu, V., Pritchard, J. R., Awuah, S. G., Lawler, S. E., Meyer, F., Dufrasne, F., & Berger, G. (2022). Self-assembled ruthenium and osmium nanosystems display a potent anticancer profile by interfering with metabolic activity. Inorganic Chemistry Frontiers. doi:10.1039/D2QI00423B
  10. 7. Dufrasne, F. (2022). Baloxavir marboxil: An original new drug against influenza. Pharmaceuticals, 15(1), 28, 11. doi:10.3390/ph15010028
  11. 8. Marloye, M., Inam, H., Moore, C. J., Debaille, V., Pritchard, J. J., Gelbcke, M., Meyer, F., Dufrasne, F., & Berger, G. (2021). Synthesis, structure and anticancer properties of new biotin- and morpholine-functionalized ruthenium and osmium half-sandwich complexes. JBIC. Journal of biological inorganic chemistry. doi:10.1007/s00775-021-01873-9
  12. 9. Soubhye, J., Van Antwerpen, P., & Dufrasne, F. (2020). A patent review of myeloperoxidase inhibitors for treating chronic inflammatory syndromes (focus on cardiovascular diseases, 2013-2019). Expert opinion on therapeutic patents. doi:10.1080/13543776.2020.1780210
    13. << Précédent 1 2 3 4 5 6 7 8 9 10 11 12 Suivant >>